| 宁鹏1，2 徐珞1.恩替卡韦联合胸腺肽α1 治疗慢性乙型肝炎疗效研究[J].,2011,11(10):1931-1933 |
| 恩替卡韦联合胸腺肽α1 治疗慢性乙型肝炎疗效研究 |
| Curative Effect of Entecavir plus Thymosin α1 for Patientswith Chronic Hepatitis B |
| |
| DOI： |
| 中文关键词: 慢性乙型肝炎 恩替卡韦 胸腺素α1 临床效果 |
| 英文关键词: Chronic hepatitis B entecavir thymosin α1 clinical therapy |
| 基金项目: |
|
| 摘要点击次数: 845 |
| 全文下载次数: 1168 |
| 中文摘要: |
| 目的：观察和比较恩替卡韦联合胸腺肽α1 治疗HBeAg 阳性慢性乙型肝炎的疗效。方法：选取我院58 例HBeAg 阳性慢性
乙型肝炎患者分成联合组和对照组。联合组28 例，初始同时使用恩替卡韦及胸腺肽α1 24 周，之后停胸腺肽α1 继续用恩替卡韦
至48 周。对照组30 例，单用恩替卡韦0.5mg／d，48 周。定期检测ALT 复常率，HBV DNA 转阴率，HBeAg／抗HBe 血清转换率，
肝纤维化组合，Fibroscan 评分两组在治疗结束时进行疗效评价。结果：24 周时两组ALT 复常率无差异显著性（P＞0.05），联合组
和对照组HBV DNA 阴转率在24 周、48 周时均差异有显著性（P＜0.05）。联合组与单用组HBeAg 血清转换率在第24 周、48 周
时，两组比较差异均有显著性（P＜0.05）。肝纤维化组合各指标（HA，LN，PIIIP，Ⅳ型胶原），Fibroscan 评分两组治疗48 周后比较差
异均有显著性（P＜0.05），且两组治疗前后差异联合组更显著。治疗过程中，未发现明显副作用。结论：恩替卡韦联合胸腺肽α1 治
疗HBeAg 阳性慢性乙型肝炎，安全性与耐受性良好，联合组在ALT 复常率，HBeAg 血清转换率和HBV DNA 转阴率，抗肝纤维
化的疗效上显著优于单用恩替卡韦组。 |
| 英文摘要: |
| Objective: To observe the effect of entecavir and thymosin α1 treatment HBeAg positive chronic patitis B patients.
Methods: 58 HBeAg-positive patients with chronic hepatitis B were divided into combination group(n=28) and control group(n=30). The
combination group was treated with entecavir and thymosinα1 for 24 weeks ,and then stopping using thymosinα1 and continuing
entecavir until 48 weeks;the control group was given entecavir (0.5mg daily) for 48 weeks, regularly testing the recovery rate ofALT,
HBV DNA negative conversion rate, HBeAg/anti-HBe seroconversion rate, combination of hepatic fibrosis. Results: At 24 weeks there
were no difference in the recovery rate of ALT between the two groups (P＞0.05), There were respectively significant differences
between the two group patients both HBeAg seroconversion rates and HBV DNA negative rate at 24 weeks, 48 weeks (P＜0.05). The
levels of liver fibrosis indexes(HA, LN, PIIIP,Ⅳ-collagen)and fibroscan score decreased significantly after treatment for 48 weeks of two
treatment groups , The differences were statistically significant (P＜0.05 ). No adverse reaction was reported during the treatment.
Conclusions: Entecavir and thymosin α1 for HBeAg positive chronic hepatitis B have a good safety and tolerability , the combination
group in the rate of ALT normalization, HBeAg seroconversion and HBV DNA negative rate, the efficacy of hepatic fibrosis is
significantly superior to the entecavir group alone. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
